The growing area of peptide and protein therapeutics research is of paramount importance to medical application and advancement. A needed reference for entry level researchers and researchers working in interdisciplinary / collaborative projects, Peptide and Protein Delivery addresses the current and emerging routes for delivery of therapeutics. Covering cerebral delivery, pulmonary delivery, transdermal delivery, intestinal delivery, ocular delivery, parenteral delivery, and nasal delivery, this resource offers an overview of the main routes in therapeutics. Researchers across biochemistry, pharmaceutical, molecular biology, cell biology, immunology, chemistry and biotechnology fields will find this publication invaluable for peptide and protein laboratory research.
Discusses the most recent data, ideas and conceptsPresents case studies and an industrial perspectiveDetails information from the molecular level to bioprocessingThought provoking, for the novice to the specialistTimely, for today's biopharmaceuticals market

Global Perspectives on Astaxanthin: From Industrial Production to Food, Health, and Pharmaceutical Applications explores the range of practical applications for this molecule, focusing on nutraceutical, pharmaceutical and cosmeceutical products, along with food and feed. This volume brings together the most relevant research, background and future thinking on astaxanthin, focusing on its health benefits. Chapters cover phytopharmaceuticals, industrial production, feeds, downstream processing, regulations, products, color, pigment, cosmetics, bioactive compounds, relationships to other carotenoids, and skin care. The detailed information on its production, processing, utilization and future applications will be of particular use to academic and industry researchers in pharmaceutical sciences, pharmacology and nutrition.

The Design and Development of Novel Drugs and Vaccines: Principles and Protocols presents both in silico methods and experimental protocols for vaccine and drug design and development, critically reviewing the most current research and emphasizing approaches and technologies that accelerate and lower the cost of product development. Sections review the technologies and approaches used to identify, characterize and establish a protein as a new drug and vaccine target, cover several molecular methods for in vitro studies of the desired target, and present various physiological parameters for in vivo studies. The book includes preclinical trials and research, along with information on FDA approval.

The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has contributed to the informative, by critically interpreting it, and by pointing to whatever is misleading.

*Provides a critical yearly survey of new data and trends *Special reviews in this Annual include, among other topics: Epidemiology of the use of ecstasy, Paracetamol and the risk of asthma, Combination vaccines/multiple immunizations, Interactions of herbal medicines with warfarin, and Tyrosine kinase inhibitors.

Delivery of therapeutic proteomics and genomics represent an important area of drug delivery research. Genomics and proteomics approaches could be used to direct drug development processes by unearthing pathways involved in disease pathogenesis where intervention may be most successful.

This book describes the basics of genomics and proteomics and highlights the various chemical, physical and biological approaches to protein and gene delivery.
Covers a diverse array of topics from basic sciences to therapeutic applications of proteomics and genomics deliveryOf interest to researchers in both academia and industryHighlights what s currently known and where further research is needed"

Without warning stroke can paralyze, blind, or kill. Some victims recover, but many do not and may even suffer another disabling or fatal attack. The drug known as tPA can drastically reduce the long-term disability associated with stroke, but despite its near-miraculous capabilities and the growing support of most neurologists, it has been slow to win acceptance as the standard of care in emergency departments nationwide.
tPA for Stroke chronicles how this remarkable drug came to be tested in stroke victims, its early years in development by the pharmaceutical giant Genentech, and its eventual marginalization due to a convergence of unfavorable political, fiscal, and medical circumstances. For instance, initially many stroke specialists were unconvinced that the drug's benefits outweigh its risks (tPA was originally developed and is still used for cardiac patients). Moreover, neurologists called upon to assess stroke patients have not typically been trained to make decisions in emergency settings--and tPA must be given within a scant few hours after stroke. These and other factors have continued to delay the drug's universal acceptance as the most effective treatment available, and to hamper the general public's awareness that such a treatment exists--a troubling state of affairs that Zivin and Simmons argue must be rectified. Instilling the knowledge that anyone, at any time, is susceptible to stroke, from the old and infirm to the young and healthy, tPA for Stroke is a clarion call to awareness in a rapidly changing healthcare environment in which stroke, long a disease in thrall to resignation and pessimism, must be neglected no longer.

Cardiovascular disease remains a major cause of death and disability in developed countries and, increasingly so, in the developing world.Presented in this volume of Advances in Pharmacology are some of the most promising possibilities for treating large numbers of individuals afflicted with these conditions

This volume contains up-to-date reviews of the most important emerging cardiovascular therapies written by world leaders in the field."

Cardiovascular disease remains a major cause of death and disability in developed countries and, increasingly so, in the developing world. Presented in this volume of Advances in Pharmacology are some of the most promising possibilities for treating large numbers of individuals afflicted with these conditions

This volume contains up-to-date reviews of the most important emerging cardiovascular therapies written by world leaders in the field.

"Annual Reports in Medicinal Chemistry "provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
* Covers findings related to cardiovascular, inflammation, and pulmonary diseases
* Examines issues in oncology, from mTor inhibitors to drug targets
* Incorporates up-to-date information on drug design and discovery, including delivery to market

This monograph was assembled to honor Professor Norman Bowery and his work on the 30th anniversary of his discovery of the GABAB receptor. In the present volume, leading neuroscientists from academia and industry provide a perspective of current research, both basic and translational, in the discovery of drugs acting at the GABAB receptor. The topics covered provide a comprehensive review of the field and the current state of research in this area. Included are chapters on the chemistry of GABAB agonists and antagonists, on the genetics and molecular composition of the site, its regulation and trafficking, and its role in controlling cellular, autonomic, and behavioral function. There are also chapters describing the potential clinical utility of drugs regulating GABAB activity receptorin the areas of hypertension, gastroesophageal reflux disease, Down syndrome, depression, and substance abuse.

The information contained in this text will be of particular interest to neuroscientists in general and to neuropharmacologists in particular.
Articles written by leading investigators in the fieldInforms and updates on all the latest developments"

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
There has been significant progress in the development of targeted therapy drugs that act specifically on certain cancers, and that minimize damage to normal cells. Oncologists and cancer researchers will rely on this volume to determine effective drug treatments.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only anticancer drugs, but also all other drugs that act upon related organ systems affected by cancer
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

Innovation in Clinical Trial Methodologies: Lessons Learned during the Corona Pandemic presents a selection of updated chapters from Re-Engineering Clinical Trials that feature innovative options and methods in clinical trials. The Coronavirus pandemic is an accelerator for digitalization in many industries, including clinical trials. This book considers best practices, alternative study concepts requiring fewer patients, studies with less patient interaction, the design of "virtualized" protocols, and moving from data to decisions. This book will be helpful to pharmacologists, physicians and clinical researchers involved in the process of clinical development and clinical trial design.

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
This volume is essential for internal medicine physicians and general practitioners who prescribe antibiotic drugs, like penicillin and tetracycline that cure bacterial infections, and antiviral drugs used to treat patients with HIV and herpes viruses.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only antimicrobial drugs, but also all other drugs that act in an anti-microbial manner
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

Inhaled medicines are widely used to treat pulmonary and systemic diseases. The efficacy and safety of these medicines can be influenced by the deposited fraction, the regional deposition pattern within the lungs and by post-depositional events such as drug dissolution, absorption and clearance from the lungs. Optimizing performance of treatments thus requires that we understand and are able to quantify these product and drug attributes. Inhaled Medicines: Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches explores the current state of the art with respect to inhalation drug delivery, technologies available to assess product performance, and novel in silico methods now available to link in vitro product performance to clinical performance. Recent developments in the latter field, especially the prospect of integration of three-dimensional Computational Fluid Particle Methods (3D-CFPD) with physiologically based pharmacokinetic (PBPK models), unlocks the potential for in silico population studies that can help inform and optimize treatment and product development strategies. In this highly multidisciplinary field, where progress occurs at the intersection of several disciplines of engineering and science, this work aims to integrate current knowledge and understanding and to articulate a clear vision for future developments.

"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

*Presents the latest research in the field of drug discovery *Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect